Phaseline

Targets › ZNT1

ZNT1 (Proton-coupled zinc antiporter SLC30A1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Aug 2027.

Zinc ion:proton antiporter that could function at the plasma membrane mediating zinc efflux from cells against its electrochemical gradient protecting them from intracellular zinc accumulation and toxicity. Alternatively, could prevent the transport to the plasma membrane of CACNB2, the L-type calcium channels regulatory subunit, through a yet to be defined mechanism. (UniProt, Q9Y6M5)

Open in Phaseline: the race on ZNT1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Anhui Provincial HospitalOral elemental zinc supplementation
Zinc supplementation (cofactor for immune cell function)
ZNT1, ZNT2Phase 2Hepatocellular CarcinomaAug 2027

Conditions

Hepatocellular Carcinoma (1)

Modalities

small molecule (1)

Companies

Anhui Provincial Hospital (1)

Related targets

ZNT2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.